Americans seeking Eli Lilly and Novo Nordisk’s weight-loss drugs turn to compounded market
An injection pen of Zepbound, Eli Lilly’s weight-loss drug ... Lilly last week reported a rare $1.5 billion sales ...
STAT13d
Eli Lilly weight loss drug shortage underscores deeper issues with FDA oversight
A turbulent series of events around the supply of Eli Lilly’s blockbuster weight loss treatment has raised concerns around ...
Novo’s New Obesity Drug Is Targeting the Most Dramatic Weight Loss Yet
The drugmaker hopes to show CagriSema leads to at least 25% weight loss, without increased side effects. Its lead in a ...
Lilly Cuts Outlook After Obesity Drug Sales Post First Miss
Eli Lilly & Co. lowered its full-year guidance Wednesday after sales of its blockbuster weight-loss drug fell short of expectations, which the company blamed on inventory issues.Most Read from Bloombe ...
Wall Street Journal8d
Eli Lilly’s Bad Quarter Doesn’t Change Long-Term Math on Obesity Bonanza
Sales of GLP-1 drugs Mounjaro and Zepbound disappointed investors. (Shelby Knowles/Bloomberg News) Eli Lilly had a bad ...
Why Eli Lilly Is a No-Brainer Stock to Buy on the Dip
Here's why Eli Lilly is a no-brainer stock to buy on the dip ... Q3 earnings call that wholesalers decreased their ...
Viking Therapeutics soars as early-stage oral obesity drug data exceeds expectations
Viking Therapeutics shares surged 25% before the bell on Monday after early-stage data from the company's experimental oral ...
Eli Lilly Stock Tumbles After Disappointing Obesity Drug Sales
Eli Lilly shares slid in premarket trading after the drugmaker reported disappointing quarterly results, with sales of its popular diabetes and anti-obesity drugs lower than expected. Lilly said inven ...